Novan Stock Forecast, Price & News

Novan (NASDAQ:NOVN) Frequently Asked Questions

Is Novan a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novan stock.
View analyst ratings for Novan or view top-rated stocks.

How has Novan's stock been impacted by COVID-19?

Novan's stock was trading at $0.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NOVN shares have increased by 792.3% and is now trading at $4.64.
View which stocks have been most impacted by COVID-19.

Are investors shorting Novan?

Novan saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 316,100 shares, a decrease of 19.5% from the October 31st total of 392,800 shares. Based on an average daily trading volume, of 330,400 shares, the short-interest ratio is currently 1.0 days.
View Novan's Short Interest.

When is Novan's next earnings date?

Novan is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Novan.

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.08. Novan had a negative trailing twelve-month return on equity of 179.38% and a negative net margin of 833.16%. During the same period in the previous year, the company earned ($0.60) EPS.
View Novan's earnings history.

What price target have analysts set for NOVN?

4 equities research analysts have issued 12 month price objectives for Novan's stock. Their forecasts range from $2.00 to $16.00. On average, they expect Novan's stock price to reach $7.00 in the next year. This suggests a possible upside of 50.9% from the stock's current price.
View analysts' price targets for Novan or view top-rated stocks among Wall Street analysts.

Who are Novan's key executives?

Novan's management team includes the following people:

• Paula Brown Stafford, Chairman, President & Chief Executive Officer
• John M. Gay, Chief Financial Officer, Secretary & VP
• Carri Geer, Chief Technology Officer & Senior Vice President
• Tomoko Maeda-Chubachi, Chief Medical Officer
• Elizabeth Messersmith, Chief Development Officer & Senior Vice President

Who are some of Novan's key competitors?

Some companies that are related to Novan include Humanigen (HGEN), Khosla Ventures Acquisition (KVSA), Longeveron (LGVN), Capstar Special Purpose Acquisition (CPSR), Nature's Sunshine Products (NATR), Adagene (ADAG), Selecta Biosciences (SELB), XBiotech (XBIT), Alpine Immune Sciences (ALPN), VistaGen Therapeutics (VTGN), ProQR Therapeutics (PRQR), Rain Therapeutics (RAIN), Clene (CLNN), Cogent Biosciences (COGT) and NRx Pharmaceuticals (NRXP).
View all of NOVN's competitors.

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and OrganiGram (OGI).

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

Who are Novan's major shareholders?

Novan's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.61%), Geode Capital Management LLC (0.72%), GSA Capital Partners LLP (0.47%), Citadel Advisors LLC (0.00%), Morgan Stanley (0.14%) and B. Riley Wealth Management Inc. (0.12%).
View institutional ownership trends for Novan.

Which major investors are selling Novan stock?

NOVN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Morgan Stanley.
View insider buying and selling activity for Novan or view top insider-selling stocks.

Which major investors are buying Novan stock?

NOVN stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Citadel Advisors LLC, Geode Capital Management LLC, and B. Riley Wealth Management Inc..
View insider buying and selling activity for Novan or or view top insider-buying stocks.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $4.64.

How much money does Novan make?

Novan has a market capitalization of $87.31 million and generates $4.92 million in revenue each year. The company earns $-29.29 million in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Novan have?

Novan employs 23 workers across the globe.

What is Novan's official website?

The official website for Novan is www.novan.com.

Where are Novan's headquarters?

Novan is headquartered at 4105 HOPSON ROAD, MORRISVILLE NC, 27560.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at (919) 485-8080, via email at cikkal[email protected], or via fax at 919-237-9212.